Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

NCT02354261 | Completed Phase 2 DMC

• 2 other identifiers: HP2001SCORING
• Study Type: interventional
• Target: 38
• Locations: 1 country
• Sites: 5

Brief Summary

The study will assess the safety and efficacy of SUBA-Cap in subjects with Basal Cell Carcinoma Nevus Syndrome.

Conditions

Basal Cell Carcinoma in Basal Cell Nevus Syndrome

Keywords

Basal Cell Carcinoma Nevus Syndrome; BCCNS; BCC; itraconazole; basal cell carcinoma; locally advanced basal cell carcinoma

Outcome Measures

Primary Outcomes (1)

• Response rate of BCC lesions

  Up to 26 weeks

Secondary Outcomes (9)

• Safety and tolerance; measured by number of subjects with adverse events

  Participants will be followed for the duration of study participation, an expected average of 26 weeks

• Number of new BCCs eligible for surgical resection

  Up to 26 weeks

• Duration of response in those subjects that have responded

  Up to 26 weeks

• Time to next therapy (systemic therapy or surgical intervention)

  Up to 26 weeks

• Change in the number of jaw cysts

  Up to 26 weeks

Study Arms (1)

SUBA-Itraconazole

EXPERIMENTAL

Subjects will receive an oral dose of 300 mg SUBA-itraconazole daily.

Drug: SUBA-Itraconazole

Interventions

SUBA-Itraconazole DRUG

Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.

Also known as: SUBA-Cap

SUBA-Itraconazole

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ECOG performance status of 0 or 1
• Diagnosis of Basal Cell Carcinoma Nevus Syndrome (BCCNS)
• Histologic confirmation of BCC from at least one lesion
• History of surgical removal of at least ten (10) prior BCCs
• Measurable disease as defined, namely at least ten (10) measurable lesions such that the sum of the longest diameters of the measurable lesions is at least 40 mm.
• Has failed, refused, or is not eligible for standard of care therapy for BCC
• Willingness to abstain from the use of non-study treatments for BCC, including but not limited to topical medications, PDT, and/or irradiation therapy.
• At least four weeks from prior major surgery
• Women who are pre-menopausal or not surgically sterile must be willing to use an acceptable contraceptive method for the duration of the study and for 30 days following the last dose of study drug
• Sexually active men must be willing to use an acceptable contraceptive method for the duration of time on study and for 30 days following the last dose of study drug
• Clinical laboratory values within the following ranges:
• Negative serum pregnancy test
• Adequate hematologic function (ANC ≥1.5 x 10\^9/L; platelet count ≥75x10\^9/L; hemoglobin ≥9g/dL (in the absence of red blood cell transfusions in the prior 14 days)
• Prothrombin time (PT-INR) or activated partial thromboplastin time (APTT) \<1.5 times the upper limit of normal range, unless currently receiving anticoagulants
• Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥60 mL/min

You may not qualify if:

• Presence of metastatic BCC
• Subjects who would be disserved significantly by a delay in conventional therapy, such as surgical intervention of their BCC
• Prior use of a hedgehog inhibitor (e.g., sonidegib, vismodegib) or Itraconazole within the past 6 months
• History of progressive disease on a hedgehog inhibitor (e.g., sonidegib, vismodegib) or other Hh pathway inhibitors for the treatment of BCC
• Pregnant and/or nursing women
• Use of any medications metabolized by the cytochrome P450 3A4 isoenzyme system (CYP3A4) known to lead to potentially serious and/or life threatening adverse events when used in conjunction with itraconazole
• Any illness that is likely to reduce absorption of oral medications
• Corrected QT (Fridericia) interval of \>450 msec for females and \>430 msec for males
• Use of any medications known to result in a prolongation of the QT interval
• History of congestive heart failure or other cardiac abnormality that would contraindicate the use of itraconazole
• Any condition or situation which in the Investigator's opinion may put the subject at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study
• Any indication of compromised liver function that would otherwise contraindicate use of itraconazole
• Any concurrent malignancy, except for squamous cell carcinoma of the skin and cervical carcinoma in situ, that is likely to require treatment within the next two years or would interfere with study requirements
• Psychiatric illness and/or social situations (e.g., excessive alcohol use or use of illicit drugs) that would interfere with study compliance
• Known HIV infection, active hepatitis B or active hepatitis C infection (testing not required unless indicated by history)

Sponsors & Collaborators

• HedgePath Pharmaceuticals, Inc.: lead

Study Sites (5)

Dermatology Specialists, Inc

Oceanside, California, 92056, United States

Location

Ameriderm Research

Ormond Beach, Florida, 32174, United States

Location

Grekin Skin Institute

Warren, Michigan, 48034, United States

Location

Stony Brook University

East Setauket, New York, 11733, United States

Location

Penn State Hershey Medical Center

Hershey, Pennsylvania, 17033, United States

Location

MeSH Terms

Conditions

Carcinoma, Basal Cell

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Basal Cell

Study Officials

• James Solomon, MD, PhD

  Ameriderm Clinical Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 21, 2015
• First Posted: February 3, 2015
• Study Start: August 7, 2015
• Primary Completion: March 1, 2019
• Study Completion: March 1, 2019
• Last Updated: August 5, 2020

Record last verified: 2020-08

Locations

US (5)